Cellectric Develops Method for Analysis in Medtech

A collaboration between Gradientech, an Uppsala-based medtech company, and Cellectric, an Austrian firm, is underway to develop faster sepsis diagnostics, according to Medtech Magazine. The companies have initiated a feasibility study to explore this potential. Cellectric, a 2021 spin-off from the Austrian Institute of Technology in Vienna, is developing a method for analyzing sepsis samples directly from blood, eliminating the need for traditional bacterial cultures. Gradientech, on the other hand, has developed a rapid antibiotic susceptibility testing technology. The combined aim is to ensure sepsis patients receive the appropriate antibiotic at the correct dosage, thereby improving treatment outcomes.